Pfizer Inc. $PFE Shares Bought by Fort Washington Investment Advisors Inc. OH

Fort Washington Investment Advisors Inc. OH boosted its stake in shares of Pfizer Inc. (NYSE:PFE) by 5.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,042,039 shares of the biopharmaceutical company’s stock after buying an additional 103,010 shares during the quarter. Fort Washington Investment Advisors Inc. OH’s holdings in Pfizer were worth $57,340,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Vermillion Wealth Management Inc. increased its holdings in Pfizer by 19.4% in the 1st quarter. Vermillion Wealth Management Inc. now owns 2,352 shares of the biopharmaceutical company’s stock valued at $66,000 after purchasing an additional 382 shares during the last quarter. Triad Wealth Partners LLC boosted its position in shares of Pfizer by 1.9% during the fourth quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company’s stock worth $510,000 after buying an additional 386 shares during the period. Eagle Capital Management LLC boosted its position in shares of Pfizer by 0.3% during the first quarter. Eagle Capital Management LLC now owns 126,573 shares of the biopharmaceutical company’s stock worth $3,554,000 after buying an additional 390 shares during the period. ETF Store Inc. grew its stake in shares of Pfizer by 3.8% in the fourth quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company’s stock valued at $272,000 after buying an additional 396 shares in the last quarter. Finally, Mattern Wealth Management LLC raised its holdings in shares of Pfizer by 4.6% in the 4th quarter. Mattern Wealth Management LLC now owns 9,161 shares of the biopharmaceutical company’s stock valued at $228,000 after buying an additional 400 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Trading Up 2.6%

NYSE:PFE opened at $24.27 on Friday. The firm has a market cap of $138.35 billion, a PE ratio of 18.53 and a beta of 0.34. The stock has a fifty day moving average price of $25.94 and a 200 day moving average price of $26.28. Pfizer Inc. has a 12-month low of $23.11 and a 12-month high of $28.75. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company had revenue of $14.45 billion for the quarter, compared to the consensus estimate of $13.84 billion. During the same quarter in the prior year, the business earned $0.92 EPS. Pfizer’s revenue was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Sell-side analysts anticipate that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be given a $0.43 dividend. The ex-dividend date is Friday, July 24th. This represents a $1.72 annualized dividend and a yield of 7.1%. Pfizer’s dividend payout ratio is 131.30%.

Analyst Ratings Changes

Several equities analysts recently issued reports on PFE shares. Wall Street Zen raised Pfizer from a “hold” rating to a “buy” rating in a research note on Sunday, June 21st. Morgan Stanley boosted their price target on shares of Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a research note on Friday, April 10th. Argus raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price target on the stock in a research report on Monday, March 2nd. Citigroup raised their price objective on shares of Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a research note on Wednesday, April 29th. Finally, Guggenheim lifted their price objective on shares of Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a report on Tuesday, March 24th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $28.82.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The FDA expanded Pfizer’s Ibrance label for frontline maintenance in advanced breast cancer, a regulatory win that could support use of the drug and modestly improve Pfizer’s oncology revenue outlook. FDA expands Pfizer’s Ibrance label for frontline maintenance in advanced breast cancer
• Positive Sentiment: Pfizer declared its third-quarter 2026 dividend of $0.43 per share, reinforcing its appeal for income-focused investors and signaling continued confidence in cash generation. Pfizer Declares Third-Quarter 2026 Dividend
• Neutral Sentiment: Pfizer Ventures participated in a $62 million Series B for Oblenio Bio, highlighting the company’s broader innovation strategy, though the investment is not likely to have an immediate material impact on PFE shares. Oblenio Bio Closes $62 Million Series B…
• Neutral Sentiment: Pfizer halted a tafamidis bioequivalence study, which appears to be a study update rather than a major commercial setback, so the market reaction is likely limited unless further details emerge. Pfizer Halts Tafamidis Bioequivalence Study
• Negative Sentiment: Recent investor concern remains tied to Pfizer’s mixed oncology pipeline news, especially the failed Phase 3 sigvotatug vedotin lung cancer study, which has pressured sentiment around the company’s long-term growth narrative. Pfizer (PFE) Is Down 7.3% After Mixed Oncology Updates Reshape Its Long-Term Pipeline Narrative

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.